SEC Company Response from Clearside Biomedical, Inc. (CLSD) (CIK 0001539029) (CLSDQ) — May 20, 2020
Clearside Biomedical, Inc. (CLSD) (CIK 0001539029)
Date: May 20, 2020 · CIK: 0001539029 · Accession: 0001193125-20-147430
AI Filing Summary & Sentiment
File numbers found in text: 333-238128
Letter
May 20, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: Alan Campbell
Celeste Murphy
Re: Clearside Biomedical, Inc.
Registration Statement on Form S-3
File No. 333-238128
Acceleration Request
Requested Date: May 22, 2020
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3, as amended (File No. 333-238128) (the “Registration Statement”) to become effective on May 22, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff.
Once the Registration Statement has been declared effective, please orally confirm that event with Brent Siler of Cooley LLP, counsel to the Registrant, at (202) 728-7040, or in his absence, either of Brian Leaf at (703) 456-8053 or Mark Ballantyne at (703) 456-8084.
[Signature page follows]
Very truly yours,
Clearside Biomedical, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 20, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Alan Campbell Celeste Murphy Re: Clearside Biomedical, Inc. Registration Statement on Form S-3 File No. 333-238128 Acceleration Request Requested Date: May 22, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3, as amended (File No. 333-238128) (the “Registration Statement”) to become effective on May 22, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with Brent Siler of Cooley LLP, counsel to the Registrant, at (202) 728-7040, or in his absence, either of Brian Leaf at (703) 456-8053 or Mark Ballantyne at (703) 456-8084. [Signature page follows] Very truly yours, Clearside Biomedical, Inc. By: /s/ Charles A. Deignan Charles A. Deignan Chief Financial Officer cc: George Lasezkay, Clearside Biomedical, Inc. Brent B. Siler, Cooley LLP Brian F. Leaf, Cooley LLP Mark Ballantyne, Cooley LLP